Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

16 Customer Reviews

  • Tumor growth of 827 GSC-derived xenografts treated with an AKT inhibitor perifosine (30 mg/kg body weight). Twenty-three days after tumor implantation in mice, perifosine was administered by intraperitoneal injection (daily for 5 days). Error bars represent SD. Five mice per group, *p < 0.01.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    Immunoblot analysis of pY-STAT3, EZH2, AKT, and trimethylated H3K27 in lysates from xenograft tumors treated with an AKT inhibitor perifosine.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • Co-IP analysis of methylated STAT3 in GBM xenograft tumors treated with perifosine.AKT inhibition in vivo decreased STAT3 methylation and pY-STAT3, but increased global levels of H3K27 trimethylation.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    IF staining of pS21 EZH2 and pY-STAT3 on the frozen sections of GBM xenografts treated with vehicle or perifosine. Nuclei were stained with DAPI. Bar represents 10 microns.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • NRP-152 cells were transfected with Id1-luciferase reporter element as described in the figure and then incubated with±perifosine (10 nmol/L)  for 2 hours, followed by±LR3-IGF-I (10 nmol/L) for 24 hours. Cells were then treated with ±BMP4 and assayed for luciferase 2 hours later.

     

     

    Cancer Res 2010 70, 9106-9117. Perifosine (KRX-0401) purchased from Selleck.

    Alkylphospholipid-induced morphological changes in HepG2 cells. Cell morphology was examined with an inverted microscope(20× original magnification). The morphology of HepG2 cells incubated with MEM/10% FBS is shown in the absence of any addition (control, A), or in the presence of 25 μM of HePC (B), edelfosine (C), ErPC (D) or perifosine (E) for 24 h. ErPC, erucylphosphocholine; FBS, fetal bovine serum; HePC, hexadecylphosphocholine; MEM, minimal essential medium.

     

     

    Brit J Pharmacol 2010 160, 355–366. Perifosine (KRX-0401) purchased from Selleck.

  •  

    LAT2 is degraded by proteasomes after treatment with alkylphospholipids. A, 3-h treatment of NB4 cells before exposure to the proteasome inhibitor MG132 (10 μM) prevented the reduction of LAT2 induced by 25 μM ODPC. B, C, a similar effect was observed after exposure (30 min) of NB4 cells to the proteasome inhibitor MLN9708 (5 μM) followed by treatment with 25 μM ODPC (B) or 25 μM perifosine (C).

    Mol Cell Proteomics 2012 11(12), 1898-1912 . Perifosine (KRX-0401) purchased from Selleck.

    (a) Validation of the global proteome and acetylome results. AS and BE2 cells were treated with 10 μM of perifosine for 16 h. Total proteins were extracted and 30 μg of protein was analyzed for integrin β5 and acetyl-Histone H2B (Lys12) by western blotting. GAPDH was used as loading control.

    Sci Rep, 2017, 7:41950. Perifosine (KRX-0401) purchased from Selleck.

  • Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. Perifosine (KRX-0401) purchased from Selleck.

    Established cell lines (A549 and H460 lines) were un-stimulated (“C”, same for all figures), or treated with indicated concentration of perifosine (0.3-10 μM) or plus ABT-737 (100 nM), cells were then cultured for indicated time, and cell growth was tested by MTT assay (a, b, d, e) or by colony formation assay (c and f). “Prf” stands for perifosine (Same for all figures). The results presented were representative of three independent experiments. The values were expressed as the means ± SD. *p < 0.05 vs “C” group. #p < 0.05 compared with the perifosine only group without ABT-737 co-treatment.

    Biochem Biophys Res Commun, 2016, 473(4):1170-6. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting analysis demonstrating Ser473p-Akt and total Akt levels in HepG2 cells and Bel-7402 cells treated with increasing concentrations of perifosine for 24 h. Betaactin served as loading control. Bands were analyzed by Glyco Band-Scan software. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05,** P<0.01 vs. control, Student,s t test

     

     

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    Induction of apoptosis in hepatoma cells by treatment for 48 h with 10 μM perifosine. The treated cells were stained with DAPI and the apoptotic morphological changes in the nuclear chromatin were observed under a fluorescent microscope.

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting assay showing cleavage of caspase-3, caspase-9 and PARP in response to perifosine treatment in hepatoma cells. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05, ** P<0.01 vs. control, Student,s t test

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    This chart showed the change of the stable transfection cells in centrosome separation after the cells were treated with perifosine(1 μM)  6 hours, 12 hours and 24 hours. "C" means the control group, and "P" means the group treated with perifosine

    2010 Zhao Jing PHD Medical College of Peking University. Perifosine (KRX-0401) purchased from Selleck.

  • TEIF (telomerase transcriptional elements-interacting factor)gene is a novel human gene and cloned from the expression library of  HeLa cell through the hTERT promoter-based yeast one-hybrid assay. And now we are trying to find the interaction between TEIF and the EGF pathway.

     

     

    2010 Zhao Jing PHD Medical College of Peking University . Perifosine (KRX-0401) purchased from Selleck.

     After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of Perifosine for 3h,followed by 15-minute  stimolation of 100ng/ml EGF.

     

     

     

    2010 Dr. Zhang of Tianjin Medical University. Perifosine (KRX-0401) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  NUfNNVBFTnWwY4Tpc44hSXO|YYm= M4T5clAvPS9zL{KuOUDPxE1? NEOzNpU{KGh? NFXXc25z\WS3Y3XzJJRp\SCkYYPhcEBESiC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44hdGW4ZXzzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFXybVIzPjB7N{i3Ny=>
T24 BC  NIiybXdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEjKblExNjVxMT:yMlUh|ryP MVGyOEBp NUiwSYNZ\W6qYX7j[ZMhe2:{YX\lcoljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImg[IVkemWjc3W= NXTwRW9iOjZyOUe4O|M>
T24 BC  M4LIUGFxd3C2b4Ppd{BCe3O|YYm= NU[zTI5qOi53IN88US=> M1\nZ|I1KGh? MlLtd4Vve2m2aYrld{BDSyClZXzsd{B1dyC|b4Lh[oVvcWJvaX7keYNm\CCjcH;weI91cWQEoB?= MUeyOlA6Pzh5Mx?=
HepG2 MmexSpVv[3Srb36gRZN{[Xl? Mnv2NlDDqM7:TR?= NXLNZ3N[OjUEoHi= MWPwdo9lfWOnczDhckBqdnSnboPlJIN6fG:ybHHzcYlkKH[jY4XvcIl7[XSrb36gZ49zemW|cH;u[Ilv\yC2bzDhJI5wfGGkbHWg[Ilt[XSjdHnvckBw\iC2aHWgSXIh[2m|dHXycpM> M4PtTlI2QTN2MkOy
U-87 MG  MkPsSpVv[3Srb36gRZN{[Xl? MYGyNOKh|ryP M4nxUFI1yqCq M3rVRYlv[3KnYYPld{Bld3WkbHWtcYVu[nKjbnWgZo92dmRic4TyeYN1fXKncx?= NEDlW|AzPTl|NEKzNi=>
HepG2 MXXGeY5kfGmxbjDBd5NigQ>? M3Lle|IxyqEQvF2= MnPhOk8zPCCq MoXtbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS NUPqfpY4OjV7M{SyN|I>
U-87 MG  MWfGeY5kfGmxbjDBd5NigQ>? MWCyNOKh|ryP MlPmOk8zPCCq M3HiSolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFzDN{1KUSClb4Ty[YF1\WRid3n0bEBEWQ>? MoDnNlU6OzR{M{K=
HepG2 NYfwbmgxTnWwY4Tpc44hSXO|YYm= NFuweI4zOMLizszN NFfxRWc3NzJ2IHi= Mn3y[IVkemWjc3XzJGxEOy2LSTDk[Ydz[WSjdHnvcuKh\nKxbTC2JIg> MmqzNlU6OzR{M{K=
U-87 MG  NFn2SWhHfW6ldHnvckBCe3OjeR?= MVGyNOKh|ryP M3zwVFYwOjRiaB?= MV\pcoNz\WG|ZYOgeIhmKGG3dH;wbIFocWNiZnz1fEAh[XRiNjDoJJdpcWynIHnubIljcXS|IITobZMh\my3eDDheEAzPGh? Mo\0NlU6OzR{M{K=
HepG2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPlepEzOC92MDFOwG0> M1nVSFI1NzR6IHi= MnTkbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M{\BRVI2QTN2MkOy
U-87 MG  NEHabINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITGSZYzOC92MDFOwG0> NWjrS4ZDOjRxNEigbC=> MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NUT2TWVUOjV7M{SyN|I>
A549 Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWwMlMuOTBizszN Ml;qNlQwPzJiaB?= MnfIbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1zyclI2Pjl5OEm5
H460 NW[4WIcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWiwMlMuOTBizszN M1XMeVI1Nzd{IHi= M2eyWYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M3y4XFI2Pjl5OEm5
A549 M1jXcmFxd3C2b4Ppd{BCe3O|YYm= NFHsR4UyNzNizszN NFrD[YI1QCCq MlyybY5lfWOnczDhdI9xfG:|aYO= MXyyOVY6Pzh7OR?=
H460 M{TqZ2Fxd3C2b4Ppd{BCe3O|YYm= M1;VflEwOyEQvF2= MYe0PEBp MWLpcoR2[2W|IHHwc5B1d3Orcx?= MkjLNlU3QTd6OUm=
A549 MVXGeY5kfGmxbjDBd5NigQ>? M4HndFMh|ryP MXi4JIg> MoqxZoxw[2u|IFHLWEBi[3SrdnH0bY9v NGC0VpczPTZ7N{i5PS=>
H460 NUWzNGxRTnWwY4Tpc44hSXO|YYm= MUSzJO69VQ>? MVe4JIg> MXricI9kc3NiQVvUJIFkfGm4YYTpc44> MWCyOVY6Pzh7OR?=
A549 MXjGeY5kfGmxbjDBd5NigQ>? NHewPG8{KM7:TR?= NWfId4NvQCCq NVnHd5ZL[myxY3vzJI1VV1KFMTygZY5lKEWUSz3NRXBMKGGldHn2ZZRqd25iY3;tZolv\WRid3n0bEBOTUtvMU[y NXz4dpJGOjV4OUe4PVk>
H460 MkPYSpVv[3Srb36gRZN{[Xl? M2LJWVMh|ryP M37wNFghcA>? MmL0Zoxw[2u|IH3UU3JEOSxiYX7kJGVTUy2PQWDLJIFkfGm4YYTpc44h[2:vYnnu[YQhf2m2aDDNSWsuOTZ{ MlfoNlU3QTd6OUm=
RMG1 M1PUO2NmdGxiVnnhZoltcXS7IFHzd4F6 M{n0N|EuOzBizszN M1L0bVczKGh? MoTE[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NHTZUpozPTVzOUG0PC=>
RMG2 MkH4R4VtdCCYaXHibYxqfHliQYPzZZk> MWOxMVMxKM7:TR?= MlPGO|IhcA>? MmPG[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MXyyOVUyQTF2OB?=
KOC7C NFexZ5RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYWxMVMxKM7:TR?= M3juUlczKGh? M4TaSYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MWeyOVUyQTF2OB?=
HAC2 MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mmj4NU0{OCEQvF2= M33oNFczKGh? M3LnXoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NULWfIg6OjV3MUmxOFg>
RMG2 MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYGxMVMxKM7:TR?= MUe0PEBp NGi0Nphl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NUXIenBKOjV3MUmxOFg>
OVISE MoL6R4VtdCCYaXHibYxqfHliQYPzZZk> NF7EPJoyNTNyIN88US=> Mme1OFghcA>? M3LweIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MVGyOVUyQTF2OB?=
SKOV3 NW\OTZBQS2WubDDWbYFjcWyrdImgRZN{[Xl? MlzvNU0{OCEQvF2= MlHKOFghcA>? MYTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NV;HbohzOjV3MUmxOFg>
A2780 M3i3RmNmdGxiVnnhZoltcXS7IFHzd4F6 MV6xMVMxKM7:TR?= NX7GNWM1PDhiaB?= MWnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MVqyOVUyQTF2OB?=
RMG1 M{Lye2Fxd3C2b4Ppd{BCe3O|YYm= M2nhPVMxKM7:TR?= NEfOV5EzPCCq NGrBem1qdmS3Y3XzJIFxd3C2b4Ppdy=> M{LSVFI2PTF7MUS4
RMG2 MXnBdI9xfG:|aYOgRZN{e2G7 NVT4ZVJoOzBizszN Mmq1NlQhcA>? NHz5fmRqdmS3Y3XzJIFxd3C2b4Ppdy=> M1XqWlI2PTF7MUS4
HCC1806 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTyNE0yOCEQvF2= NG\hWHQ1QCCq MmjOSWM2OD1{Lki05qCKyrIkgJmwMlA4KM7:TR?= MlruNlUzQTN3N{[=
MDA-MB-231  NFGybINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H6WlAuOTBizszN NWXQ[HRCPDhiaB?= MVjFR|UxRTFwMURihKnDueLCiUCuNFch|ryP MojmNlUzQTN3N{[=
GL-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DjZ|AvOeLCk{GwNQKBkc7:TR?= M4nnZVQ5KGh? MonJTWM2OD17LkmxJO69VQ>? MkPENlQ5QDF3MEi=
CLBL-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDENE4y6oDVMUCw5qCK|ryP MWm0PEBp NVX5dGd3UUN3ME2zN{4xKM7:TR?= MVGyOFg5OTVyOB?=
UL-1 M1\QWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP2XnQxNjIkgKOxNFDjiIoQvF2= MU[0PEBp NHjqdpdKSzVyPUeuNFEh|ryP MXKyOFg5OTVyOB?=
Ema NIHGPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUewMlHjiJNzMEFihKnPxE1? NEPTWlg1QCCq MXfJR|UxRTV6Lkeg{txO NF22cWczPDh6MUWwPC=>
PANC-1 NUDjSWN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nhdVAuOjVizszN M3vwWFczKGh? NEjGWmVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NU[5[257OjR3MUm3OVE>
MIA MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfNXWMxNTJ3IN88US=> M2jIXlczKGh? MlqwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M1;GTVI1PTF7N{Wx
AsPC-1 MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHNXYQxNTJ3IN88US=> NFzJRo84OiCq Mk\zbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MXqyOFUyQTd3MR?=
PANC-1 M{P2bmZ2dmO2aX;uJGF{e2G7 M3rB[lAvPSEQvF2= NFPzOWYzPCCq NICyXY1qdmirYnn0d{BCc3RuIGO2T|EtKGGwZDDFdosyNzJicHjvd5Bpd3K7bHH0bY9vyqB? MV[yOFUyQTd3MR?=
MIA MnrMSpVv[3Srb36gRZN{[Xl? Mn;5NE42KM7:TR?= M2nRfFI1KGh? NUHjc4x{cW6qaXLpeJMhSWu2LDDTOmsyNCCjbnSgSZJsOS9{IIDoc5NxcG:{eXzheIlwdsLi NHH5VXYzPDVzOUe1NS=>
AsPC-1 MY\GeY5kfGmxbjDBd5NigQ>? NFXS[ZExNjVizszN MmezNlQhcA>? M1ywTolvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb|EwOiCyaH;zdIhwenmuYYTpc47DqA>? MmLKNlQ2OTl5NUG=
U87MG NXX3VWRES2WubDDWbYFjcWyrdImgRZN{[Xl? MUKwMVI2KM7:TR?= M2HveVI1NTl4IHi= M2flfIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MlyzNlQxPjV3MkK=
SGC7901  M3fyVWZ2dmO2aX;uJGF{e2G7 NWns[pBZOC55NT:xNOKh|ryP NUHqV4tvPDhiaB?= NWrseoFm\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh NH7E[JUzOzlzMkK0Oi=>
MGC803  NUn3WYVXTnWwY4Tpc44hSXO|YYm= Mk[4NE44PS9zMNMg{txO MnL3OFjDqGh? MmXm[IVkemWjc3XzJJAuSWu2IDjT[ZIhPDd|KTygdE1IW0t|zsKgLHNmeiB7KTygZY5lKENvTWnDJIxmfmWuc9Mg MYqyN|kyOjJ2Nh?=
TykNu M2PDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrsTWM2OD1|LkWg{txO NHjwWXMzOzh5N{CxNi=>
TykNuR M1rmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\lfmpKSzVyPUWuOUDPxE1? MWGyN|g4PzBzMh?=
M41 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJ2Lkeg{txO M1GxO|I{QDd5MEGy
M41R NIi3UVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF7Lkig{txO NX\mW2k2OjN6N{ewNVI>
OVCAR8 NGLsZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX2cYVmUUN3ME2zNU4yKM7:TR?= MUGyN|g4PzBzMh?=
HeyA8 NYToW5dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\TTWM2OD1{ND6zJO69VQ>? M1XtXFI{QDd5MEGy
A2780CP NFrETFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm2Uo5KSzVyPUeuOkDPxE1? NYC2[25POjN6N{ewNVI>
OVCAR5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT0O5lNUUN3ME22Mlch|ryP MXyyN|g4PzBzMh?=
A2780S NYm5d4p3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrMflVKSzVyPUG0MlUh|ryP MofCNlM5PzdyMUK=
MCAS M4XLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF{LkWg{txO NEnW[5IzOzh5N{CxNi=>
NCI-H727 MmXqR4VtdCCYaXHibYxqfHliQYPzZZk> NICxOXIxNTFyMDFOwG0> NF7Ud3czPC95MjDo Ml3l[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NXXVTos6OjJ2OUm0N|c>
GOT1 MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3rnTlAuOTByIN88US=> MVmyOE84OiCq M{PqV4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MknqNlI1QTl2M{e=
BON1 MWnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVTmNXpxOC1zMECg{txO M1XZVFI1Nzd{IHi= Mo\G[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy M2jHOlIzPDl7NEO3
BON1 M3fGcWFxd3C2b4Ppd{BCe3O|YYm= MY[wMVExKM7:TR?= NVm3eVRWOjRiaB?= MVnpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 MnLJNlI1QTl2M{e=
BON1 M3LCVWZ2dmO2aX;uJGF{e2G7 MlvSO{42NzFyIN88US=> NG\2Xmk5KGh? MWnk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[geIhmKGGwdHmtZZBweHSxdHnjJJBzd3SnaX7zJGJEVDJiYX7kJGJkdC2[TB?= MViyNlQ6QTR|Nx?=
Kasumi-1 NWjsfJVnS2WubDDWbYFjcWyrdImgRZN{[Xl? Mlm0NE0zOCEQvF2= Mm\KNlQwPDhiaB?= MWHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NHLNfFAzOjRyN{KyPC=>
HL-60 NF\DWmFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVmwMVIxKM7:TR?= NILlbogzPC92ODDo NGLqRlBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MnLTNlI1ODd{Mki=
Kasumi-1 NEfVXIlCeG:ydH;zbZMhSXO|c3H5 MXexNEDPxE1? NVv5fGhVOjRiaB?= MVfpcoR2[2W|IHHwc5B1d3Orcx?= MWKyNlQxPzJ{OB?=
HL-60 M{HZdWFxd3C2b4Ppd{BCe3O|YYm= M1vZb|ExKM7:TR?= M3vWelI1KGh? NXKwUJU4cW6mdXPld{BieG:ydH;zbZM> MWCyNlQxPzJ{OB?=
Kasumi-1 NYfzfJpvTnWwY4Tpc44hSXO|YYm= Mn3KNk42NzVxMUCg{txO NVvmSYE{OjRiaB?= NIj6UZll\WO{ZXHz[ZMhSWu2IHHu[EBxNUGtdDDs[ZZmdHQEoHTvd4Uu\GWyZX7k[Y51dHl? M4XqSVIzPDB5MkK4
HL-60 M{P6XWZ2dmO2aX;uJGF{e2G7 Mme5Nk42NzVxMUCg{txO M{fnVFI1KGh? NWi1dIhJ\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy|wrDkc5NmNWSncHXu[IVvfGy7 M17v[FIzPDB5MkK4
Kasumi-1 NF2xWmVHfW6ldHnvckBCe3OjeR?= M2LLVVIvPS93L{GwJO69VQ>? M1flelI1KGh? MoPHbY5lfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEqQS{GvNkBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NVznNpFLOjJ2MEeyNlg>
HL-60 MmjtSpVv[3Srb36gRZN{[Xl? NX7pd2ZUOi53L{WvNVAh|ryP MVyyOEBp MY\pcoR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NYHlZmNiOjJ2MEeyNlg>
K562 NH\HfIpHfW6ldHnvckBCe3OjeR?= MoToNlAh|ryP NYi2eFV6PDhiaB?= NWDXbJhHcW6mdXPld{BifXSxcHjh[5nDqA>? NX;tO|YxOjJ2MEeyNlg>
OCUT1 NHjLPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jvNlAvOS1|IN88US=> NV33XYhuPSCm MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MnrwNlIxQTB{N{G=
K1 NFvUZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rvTVAvOS1|IN88US=> NWfzTWU1PSCm NEnYepdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MV2yNlA6ODJ5MR?=
OCUT1 NF;lUWtHfW6ldHnvckBCe3OjeR?= NUK2No1UOyEQvH2= NXHIZYtDOjRiaB?= M4TOfYNifXOnczDhJIRz[W2jdHnjJIlv[3KnYYPlJIlvKEd{L12gdIhie2V? MWGyNlA6ODJ5MR?=
CaOV3 M{WzdmNmdGxiVnnhZoltcXS7IFHzd4F6 M{\WV|EwPS9zMDFOwG0> M3O5[|Q5KGh? NX30V3NQ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXyJINwfHKnYYTl[EB4cXSqIIDhZ4xqfGG6ZXy= NF;ESFgzOTd5NUC1OC=>
SKOV3 M3\oVGN6fG:2b4jpZ4l1gSCDc4PhfS=> NHywWXo2KM7:TR?= Mn3rOFghcA>? MorC[Y5p[W6lZYOgdIFkdGm2YYjlcEBqdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> Ml\kNlE4PzVyNUS=
A2780 M{LEOmN6fG:2b4jpZ4l1gSCDc4PhfS=> MWq1JO69VQ>? M2TzRlQ5KGh? NUXhV3Rj\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? MoKzNlE4PzVyNUS=
HT-29  NGfPepFEgXSxdH;4bYNqfHliQYPzZZk> MYS1JO69VQ>? MWm0PEBp M4jwXIVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> MYGyNVc4PTB3NB?=
A498 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37hc|AuPDBizszN MlTkO|IhcA>? Ml:wbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MkPLNlE3PDRyNUC=
CAKI-1 NW\ZSo5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XFdFAuPDBizszN M2PkWVczKGh? MkDaTWM2OH5zMDFOwG0> Mn;JNlE3PDRyNUC=
769-P M4KwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XENFAuPDBizszN NXjBXI1iPzJiaB?= NVfodIZKUUN3MI61MVExKM7:TR?= NYW2N5JDOjF4NESwOVA>
786-0 NIH0T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i1WlAuPDBizszN MVW3NkBp NYTVOod2UUN3MI61JO69VQ>? NXL6dYpSOjF4NESwOVA>
786-O MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLmS|RXOC1{MDFOwG0> NEnNd|Y4OiCq M2rWfolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M3LHT|IyPjR2MEWw
CAKI-1 M1yzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHuNIEyOC1{MDFOwG0> MWC3NkBp M{jUWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NFOyU|kzOTZ2NEC1NC=>
769-P NEPNc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f4TFAuOjBizszN NXzHVol3PzJiaB?= NYjt[4NycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHXqcFUzOTZ2NEC1NC=>
A498 NIDRSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOwMVIxKM7:TR?= MVO3NkBp MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> Ml2zNlE3PDRyNUC=
CWR22RV1 M1XuemNmdGxiVnnhZoltcXS7IFHzd4F6 M1PUNlExKM7:TR?= Mnv3NlQhcA>? NEjPSZVqdmO{ZXHz[ZMhe2Wwc3n0bZZqfHlib3[gbJVu[W5iQ2fSNlJTXjFiY3XscJMhfG9icnHkbYF1cW:w M4PYdFIyPDl4Mkez
CWR22RV1 MmDrRZBweHSxc3nzJGF{e3OjeR?= MoLJNVAh|ryP MUeyOEBp NH\Rb|hmdmijbnPld{Bz[WSrYYTpc44hcW6mdXPl[EBieG:ydH;zbZM> M{DCPVIyPDl4Mkez
CWR22RV1 M4HiXmZ2dmO2aX;uJGF{e2G7 NIj2VpM2KM7:TR?= M2f4cVI1KGh? MYXy[YR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDBb5Qhe2mpbnnmbYNidnSueR?= NUPlWm43OjF2OU[yO|M>
HepG2  NE[yVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTvdZVwPS9zMD:yNE81OCEQvF2= NF74[o0zPC92OD:3NkBp NH\3b4dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MkXWNlA5PDJ2MkW=
Bel-7402 NV;HVXN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TUW|UwOTBxMkCvOFAh|ryP MnrRNlQwPDhxN{KgbC=> MnHqbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUm2emd5OjB6NEK0NlU>
HepG2  NVT2fJlzTnWwY4Tpc44hSXO|YYm= NHPicYc2NzFyL{KwJO69VQ>? NYfMe41WOjRiaB?= M13oWpJme3WudIOgbY4hfGinIHHjZ5VufWyjdHnvckBw\iClZXzsJI52dWKncjDpckB1cGViR{KvUUBxcGG|ZR?= NWPJfHR4OjB6NEK0NlU>
Bel-7402 NEPzOJRHfW6ldHnvckBCe3OjeR?= MnXpOU8yOC9{MDFOwG0> M4HoO|I1KGh? MlzQdoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn MXiyNFg1OjR{NR?=
HepG2  M4\mbmFxd3C2b4Ppd{BCe3O|YYm= MkDpOU8yOC9{MDFOwG0> NVLwOGN1OjRxNEigbC=> MXXpcoR2[2W|IHHwc5B1d3OrczDheEB1cGVibH;u[{11cW2nIHX4dI9{fXKn MoXTNlA5PDJ2MkW=
Bel-7402 M{DiO2Fxd3C2b4Ppd{BCe3O|YYm= MnjWOU8yOC9{MDFOwG0> NIX4dIgzPC92ODDo MnLmbY5lfWOnczDhdI9xfG:|aYOgZZQhfGinIHzvcocufGmvZTDlfJBwe3W{ZR?= Mlr5NlA5PDJ2MkW=
OAW-42 NXW3OoJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKwMVQxKM7:TR?= M2ntelczyqCq M3TQXGlEPTC-MUCg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NVz4UGc6OjB2MEWyPVY>
PA-1  M4G5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTBNE01OCEQvF2= M3LPOlczyqCq NUfMS3c5UUN3MI6yOUDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NXnWT3BnOjB2MEWyPVY>
SKOV3  M4r2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTHTWVrOC12MDFOwG0> M13PblczyqCq NXywbodFUUN3MI6zNEDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy Mor3NlA1ODV{OU[=
A2780 M4rjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILwTm8xNTJyIN88US=> NVi1T|lPPDhxN{KgbC=> MYPJR|UxyqB;wrCzxsDPxG1? NFrI[3kzODRyNUK5Oi=>
A2780cis  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PuXlAuOjBizszN NGrE[4I1QC95MjDo MXvJR|UxyqB;wrC2xsDPxG1? MortNlA1ODV{OU[=
SKW6.4 NXjmR4pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGyMVExyqEQvF2= M3;IVFQ5yqCq MnrSbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M3LDd|IxOTNyOU[w
MAVER Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3SyWVIuOTEEoN88US=> MWK0POKhcA>? M3HSOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NVT5d3Q4OjBzM{C5OlA>
BJAB NHLOO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO2Nk0yOMLizszN M2rVR|Q5yqCq MX3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NUnMZmVnOjBzM{C5OlA>
OCI MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDPU2IzNTFywrFOwG0> M4G0T|Q5yqCq NIPaUY5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MoDLNlAyOzB7NkC=
MOLM M1e2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPCOlkzNTFywrFOwG0> MlTJOFjDqGh? NF\BblRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NIW3b2gzODF|MEm2NC=>
HL-60 NEfPOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK5dJFCOi1zMNMg{txO M4TTdFQ5yqCq MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NV3jNWVXOjBzM{C5OlA>
SKW6.4 NX3ET3R7SXCxcITvd4l{KEG|c4PhfS=> NIrYSW0yOMLizszN MkXUNlQwPDhiaB?= M{fHVolv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= M{P3T|IxOTNyOU[w
MAVER NYLF[4RlSXCxcITvd4l{KEG|c4PhfS=> NHHKVZQyOMLizszN MmXhNlQwPDhiaB?= MYjpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 M{LLS|IxOTNyOU[w
BJAB MVzBdI9xfG:|aYOgRZN{e2G7 MYSxNOKh|ryP MXiyOE81QCCq M{D5WYlv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= MmnZNlAyOzB7NkC=
OCI NGHnS5pCeG:ydH;zbZMhSXO|c3H5 NFe4XlQyOMLizszN NXS2bHdVOjRxNEigbC=> M1HOV4lv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= MUiyNFE{ODl4MB?=
MOLM NU\wT|FZSXCxcITvd4l{KEG|c4PhfS=> M2HTSVExyqEQvF2= MkjuNlQwPDhiaB?= MYjpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 M2XyelIxOTNyOU[w
HL-60 NHzKSYdCeG:ydH;zbZMhSXO|c3H5 NYjyZZBzOTEEoN88US=> M1PnfFI1NzR6IHi= M3;1Z4lv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= M2[3V|IxOTNyOU[w

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
+ Expand

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
+ Expand
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
in solvent
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01051557 Terminated Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm National Cancer Institute (NCI) January 27 2010 Phase 1|Phase 2
NCT01224730 Completed Cancer AEterna Zentaris January 24 2012 Phase 1
NCT02238496 Unknown status Brain Tumor Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3
NCT01049841 Completed Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01002248 Terminated Multiple Myeloma AEterna Zentaris|Dana-Farber Cancer Institute December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID